Dupixent
FDA Delays Dupixent Decision for COPD by Three Months, EMA Recommends Approval
FDA, Dupixent, COPD, EMA, Regeneron, Sanofi, Priority Review, PDUFA, Boreas, Notus, Phase III Trials
Sanofi Eyes COPD Treatment as Major Growth Driver for Dupixent, Says CEO
Sanofi, Dupixent, COPD, growth pillar, immunology, CEO, treatment, expansion, clinical trials, asthma, atopic dermatitis.
Sanofi, Regeneron Win Dupixent Label Expansion to Treat Eosinophilic Esophagitis
Eosinophilic esophagitis, Dupixent, Child, Treatment intent, sanofi, Regeneron